GLP-1 Eats Everything
Weight-loss drugs at scale change grocery baskets, snack volumes, and downstream medical demand. The manufacturers compound; packaged food and high-calorie restaurant volume absorbs the hit.
How this story could end...
The endings this story genuinely supports, written from the same evidence as the story updates. The value ranges are illustrative examples of how the affected companies as a group could re-rate — not forecasts, targets or advice.
Mapping out the endings…
How the two sides have traded
The bull and bear baskets for this story, equal-weighted and indexed so the two lines start together.
Each scenario's basket — 3 months
Both sides on one chart — 10 stocks on the bull side, 10 stocks on the bear side. Neither side is emphasised.
Each line tracks the 10 companies most exposed to this story, so a broad basket of loosely related names does not flatten it. The full list below is unchanged.
Jul 20, 2026 – Oct 19, 2026 · 66 sessions
Equal-weighted performance of the 10 most exposed stocks over the last 3 months.
No data for ZEAL
Most affected stocks
Bull case
Avantor supplies pharmaceutical-grade chemicals, single-use products, and laboratory consumables used throughout injectable-drug development and production.
Hanmi has a differentiated obesity pipeline led by long-acting multi-agonist candidates targeting GLP-1, GIP and glucagon pathways.
The proliferation of obesity-drug programs supports demand for Thermo Fisher's clinical-trial, bioprocessing and contract-manufacturing services.
IQVIA benefits from the large number of obesity, combination-therapy, and cardiometabolic clinical trials requiring outsourced research and data services.
Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.
Pfizer's obesity pipeline and dealmaking capacity offer substantial upside if it can establish a competitive next-generation weight-loss franchise.
Pemvidutide offers direct exposure to the obesity and metabolic-liver-disease markets, including demand for therapies with favorable body-composition outcomes.
Scholar Rock is developing muscle-preservation therapies intended to complement GLP-1 weight loss and address loss of lean mass.
MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.
Stevanato supplies syringes, cartridges and drug-delivery systems needed to manufacture and package injectable GLP-1 therapies.
Bear case
Reduced meal size and carbohydrate intake could weigh on unit volumes for Flowers Foods' packaged breads, buns, and sweet baked goods.
Successful obesity treatment could eventually reduce diabetes and hypertension complications, slowing growth in the population progressing to kidney failure and dialysis.
Lower progression to insulin-dependent type 2 diabetes would constrain the incremental addressable market for Insulet's Omnipod pumps, although type 1 demand remains intact.
Jack in the Box is exposed to lower fast-food frequency and smaller orders among consumers whose appetites are suppressed by obesity drugs.
Dine Brands' IHOP and Applebee's concepts depend on large portions, add-ons, and indulgent dining occasions that GLP-1 adoption could diminish.
Lindt's concentrated exposure to premium chocolate makes it vulnerable to fewer indulgence occasions and smaller serving sizes among GLP-1 users.
B&G Foods' portfolio of shelf-stable and snack-oriented brands faces volume risk if GLP-1 users buy fewer processed, calorie-dense groceries.
Post is exposed to weaker volumes in calorie-dense cereals, refrigerated foods, and snacks as medicated consumers shrink portions and alter grocery baskets.
Lower appetite and reduced caloric intake could pressure customer frequency, order size and add-on purchases at McDonald's.
Starbucks could see lower food attachment and reduced demand for high-calorie customized beverages as GLP-1 adoption broadens.
Reporting behind this story
Looking at what moved this story…